{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:30:33Z","timestamp":1774737033716,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Comput Assist Tomogr"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Clinical research has shown unique tumor behavioral characteristics of <jats:italic toggle=\"yes\">BRCA<\/jats:italic>-associated protein-1\u2013 (<jats:italic toggle=\"yes\">BAP1<\/jats:italic>-) and fibroblast growth factor receptor (<jats:italic toggle=\"yes\">FGFR<\/jats:italic>)\u2013mutated intrahepatic cholangiocarcinomas (CCAs), with <jats:italic toggle=\"yes\">BAP1<\/jats:italic>-mutated tumors demonstrating more aggressive forms of disease and <jats:italic toggle=\"yes\">FGFR<\/jats:italic>-altered CCAs showing more indolent behavior. We performed a retrospective case-control study to evaluate for unique imaging features associated with BAP1 and FGFR genomic markers in intrahepatic CCA (iCCA).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Multiple imaging features of iCCA at first staging were analyzed by 2 abdominal radiologists blinded to genomic data. Growth and development of metastases at available follow-up imaging were also recorded, as were basic clinical cohort data. Types of iCCA analyzed included those with <jats:italic toggle=\"yes\">BAP1<\/jats:italic>, <jats:italic toggle=\"yes\">FGFR<\/jats:italic>, or both alterations, as well as cases with low mutational burden or mutations with low clinical impact, which served as a control or \u201cwild-type\u201d group. There were 18 cases in the <jats:italic toggle=\"yes\">FGFR<\/jats:italic> group, 10 with <jats:italic toggle=\"yes\">BAP1<\/jats:italic> mutations, and 31 wild types (controls).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Cases with <jats:italic toggle=\"yes\">BAP1<\/jats:italic> mutations showed significantly larger growth at first year of follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03) and more frequent tumor-associated biliary ductal dilatation (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04) compared with controls. <jats:italic toggle=\"yes\">FGFR<\/jats:italic>-altered cases showed more infiltrative margins compared with controls (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.047) and demonstrated less enhancement between arterial to portal venous phases (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02). <jats:italic toggle=\"yes\">BAP1<\/jats:italic> and <jats:italic toggle=\"yes\">FGFR<\/jats:italic> groups had more cases with stage IV disease at presentation than controls (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.025, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Compared with wild-type iCCAs, <jats:italic toggle=\"yes\">FGFR<\/jats:italic>-mutated tumors often demonstrate infiltrative margins, and <jats:italic toggle=\"yes\">BAP1<\/jats:italic> tumors show increased biliary ductal dilatation at presentation. <jats:italic toggle=\"yes\">BAP1<\/jats:italic>-mutated cases had significantly larger growth at first-year restaging.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rct.0000000000001638","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T14:06:27Z","timestamp":1720188387000},"page":"868-874","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Radiogenomics of Intrahepatic Cholangiocarcinoma: Correlation of Imaging Features With BAP1 and FGFR Molecular Subtypes"],"prefix":"10.1097","volume":"48","author":[{"given":"Veronica","family":"Cox","sequence":"first","affiliation":[{"name":"Department of Abdominal Imaging"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunseon","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"bib1-20250802","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1148\/radiol.13112553","article-title":"Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes","volume":"268","year":"2013","journal-title":"Radiology"},{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1148\/radiol.14140848","article-title":"Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib3-20250802","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1148\/radiol.14140789","article-title":"ALK molecular phenotype in non\u2013small cell lung cancer: CT radiogenomic characterization","volume":"272","year":"2014","journal-title":"Radiology"},{"key":"bib4-20250802","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","article-title":"CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non\u2013small cell lung cancer","volume":"26","year":"2016","journal-title":"Eur Radiol"},{"key":"bib5-20250802","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41419-018-1087-7","article-title":"BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1\/2 and JNK\/c-Jun pathways","volume":"9","year":"2018","journal-title":"Cell Death Dis"},{"key":"bib6-20250802","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","article-title":"Hepatocellular carcinoma: clinical frontiers and perspectives","volume":"63","year":"2014","journal-title":"Gut"},{"key":"bib7-20250802","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3350\/cmh.2018.1007","article-title":"Radiomics and radiogenomics of primary liver cancers","volume":"25","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"bib8-20250802","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1148\/rg.2021210009","article-title":"Pathologic, molecular, and prognostic radiologic features of hepatocellular carcinoma","volume":"41","year":"2021","journal-title":"Radiographics"},{"key":"bib9-20250802","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","year":"2014","journal-title":"PloS One"},{"key":"bib10-20250802","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1148\/radiol.13130663","article-title":"Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations","volume":"270","year":"2014","journal-title":"Radiology"},{"key":"bib11-20250802","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1073\/pnas.1525735113","article-title":"Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma","volume":"113","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib12-20250802","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1414789111","article-title":"Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib13-20250802","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","year":"2010","journal-title":"Science"},{"key":"bib14-20250802","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1136\/bjophthalmol-2014-305047","article-title":"Prognostic parameters in uveal melanoma and their association with BAP1 expression","volume":"98","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"bib15-20250802","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","article-title":"Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations","volume":"133","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib17-20250802","first-page":"1","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"bib18-20250802","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","year":"2016","journal-title":"Cancer"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.11101777","article-title":"Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern\u2014correlation with clinicopathologic findings","volume":"260","year":"2011","journal-title":"Radiology"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1148\/radiol.2381041765","article-title":"Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma","volume":"238","year":"2006","journal-title":"Radiology"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004728-199203000-00006","article-title":"Delayed enhancement of fibrotic areas in hepatic masses: CT-pathologic correlation","volume":"16","year":"1992","journal-title":"J Comput Assist Tomogr"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00261-018-1505-4","article-title":"Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?","volume":"43","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"bib24-20250802","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00261-015-0438-4","article-title":"CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes","volume":"40","year":"2015","journal-title":"Abdom Imaging"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00330-016-4386-3","article-title":"Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of dynamic hepatic CT\u2014correlation with clinicopathological findings","volume":"27","year":"2017","journal-title":"Eur Radiol"},{"key":"bib26-20250802","doi-asserted-by":"crossref","first-page":"101696","DOI":"10.1016\/j.suronc.2021.101696","article-title":"Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma","volume":"40","year":"2022","journal-title":"Surg Oncol"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T23:12:40Z","timestamp":1754176360000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001638","relation":{},"ISSN":["1532-3145","0363-8715"],"issn-type":[{"value":"1532-3145","type":"electronic"},{"value":"0363-8715","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}